Envoy Medical®, Inc. ("Envoy Medical") (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today ...

The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC deficiency, is a significant milestone for the company. It is the first gene therapy directly administered to the brain and ...

The guidelines took years to finalize, but while regulators were drafting them, a new trend emerged: online pharmaceutical ...

The FDA designated 166 products under its breakthrough devices program in its most recent financial year, reversing the ...

BridgeBio Pharma’s acoramidis shows improved survival data, boosting approval chances. Read why BBIO stock could see gains if ...

Highlights and Recent Events Approval by U.S. Food and Drug Administration (FDA) of ORLYNVAH TM for uUTI: On October 25, 2024, Iterum received approval from the FDA of its new drug application (NDA) ...

PTC Therapeutics' gene therapy is already approved in the European Union, Great Britain, and Israel. The drugmaker will also ...

Clene’s cash, cash equivalents and marketable securities totaled $14.6 million as of September 30, 2024, compared to $35.0 million as of December 31, 2023. Clene expects that its resources as of ...

Urogen's UGN-102 presents a $5B market opportunity for bladder cancer treatment, despite risks. Read more about URGN stock ...

“We also announced that the FDA has approved our IDE application allowing us to move ... InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information ...

In the rainy season of 2020, the Forestry Development Authority (FDA) investigated the scale of abandoned logs in Grand Bassa ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) (“KalVista”), today announced the closing of a synthetic royalty financing agreement with DRI Healthcare Trust (“DRI”) for up to $179 million, comprised ...